AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Immuneering Corp (NASDAQ:IMRX)
2.0205 USD
-0.350 14.747%Sponsored Reports
Loading...
| Previous Close (in USD) | 2.37 |
|---|---|
| Change | -0.350 14.747% |
| 52 W H/L (in USD) | 11.920/1.350 |
| EBITDA (in USD) | -58.693M |
| PE Ratio | -- |
| Volume | 20386819 |
| Diluted Eps TTM | -1.86 |
| Total Assets (in USD) | 102.585M |
|---|---|
| Total Liabilities (in USD) | 12.008M |
| Revenue TTM (in USD) | 0M |
| Cash (in USD) | 59.406M |
| Market Cap (in USD) | 42.674 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 0.159M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Employees: 65
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. | Co-Founder, Pres, CEO & Director | 1983 |
| 2. | Dr. Brett M. Hall Ph.D. | Chief Scientific Officer | 1968 |
| 3. | Ms. Mallory Morales CPA | VP of Fin., Principal Financial & Accounting Officer and Treasurer | 1983 |
| 4. | Ms. Paula George CPA | Sr. Mang. of Accounting & Operations | NA |
| 5. | Mr. Michael D. Bookman J.D. | Gen. Counsel & Sec. | 1988 |
| 6. | Ms. Leah R. Neufeld | Chief People Officer | NA |
| 7. | Dr. Scott Barrett M.D. | Chief Medical Officer | 1963 |
| 8. | Dr. Mohamedi Kagalwala M.B.A., Ph.D. | Head of Neuroscience Devel. | NA |
| 9. | Dr. Peter King Ph.D. | Head of Discovery & VP | NA |
| 10. | Dr. Rajaraman Krishnan Ph.D. | Head of Neuroscience Discovery | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-2.380 3.090% | 75.51 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-3.160 4.035% | 77.64 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-2.280 0.506% | 449.43 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-3.845 0.736% | 519.27 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -50.514M | -33.843M | -17.04M | -7.709M |
| Minority Interest | - | - | - | - |
| Net Income | -49.282M | -33.536M | -17.04M | -8.061M |
| Selling General Administrative | 15.607M | 8.272M | 3.11M | 2.709M |
| Gross Profit | 0.159M | 0.927M | 1.031M | 0.697M |
| Reconciled Depreciation | 0.797M | 0.159M | 0.079M | 0.018M |
| Ebit | -51.745M | -34.045M | -17.083M | -6.291M |
| Ebitda | -51.715M | -33.886M | -16.961M | -7.34M |
| Depreciation And Amortization | 0.03M | 0.159M | 0.122M | -1.049M |
| Operating Income | -51.745M | -33.886M | -17.083M | -6.291M |
| Other Operating Expenses | 52.062M | 35.966M | 19.394M | 8.211M |
| Interest Expense | 1.014M | 0.202M | 0.043M | 0.351M |
| Tax Provision | 0M | -0.307M | - | - |
| Interest Income | 1.014M | 0.17M | 0.043M | 0.058M |
| Net Interest Income | 1.014M | 0.17M | 0.043M | -1.418M |
| Income Tax Expense | -1.232M | -0.307M | -0.043M | 0.351M |
| Total Revenue | 0.317M | 2.08M | 2.312M | 1.92M |
| Total Operating Expenses | 51.904M | 34.813M | 18.114M | 6.988M |
| Cost Of Revenue | 0.158M | 1.153M | 1.28M | 1.223M |
| Total Other Income Expense Net | 1.231M | 0.043M | 0.043M | -1.418M |
| Net Income From Continuing Ops | -50.514M | -33.536M | -17.04M | -7.709M |
| Net Income Applicable To Common Shares | -50.514M | -33.536M | -17.04M | -7.709M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 102.585M | 122.367M | 166.705M | 38.423M | 14.099M |
| Intangible Assets | 0.38M | 0.409M | 0.439M | - | - |
| Other Current Assets | 3.418M | 3.21M | 2.889M | 0.141M | 0.071M |
| Total Liab | 12.008M | 12.517M | 10.725M | 60.904M | 20.626M |
| Total Stockholder Equity | 90.576M | 109.85M | 155.98M | -22.481M | -6.527M |
| Other Current Liab | 0.26M | 4.521M | 3.965M | 0.699M | 0.21M |
| Common Stock | 0.029M | 0.026M | 0.026M | 0.005M | 0.005M |
| Capital Stock | 0.029M | 0.026M | 0.026M | 0.005M | 0.005M |
| Retained Earnings | -163.259M | -109.787M | -59.273M | -25.738M | -8.698M |
| Good Will | 6.69M | 6.69M | 6.702M | - | - |
| Other Assets | - | 0.744M | 0.102M | 0.014M | - |
| Cash | 59.406M | 72.637M | 74.888M | 37.09M | 13.782M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 7.846M | 8.054M | 5.634M | 2.256M | 0.505M |
| Current Deferred Revenue | 5.174M | - | - | - | - |
| Net Debt | -54.943M | -67.795M | -69.523M | -36.469M | -13.782M |
| Short Term Debt | 0.3M | 0.379M | 0.274M | 0.076M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 4.463M | 4.842M | 5.365M | 0.621M | - |
| Other Stockholder Equity | 253.806M | -122147.642M | -166489.556M | 3.251M | 2.166M |
| Property Plant Equipment | - | 1.37M | 0.807M | 0.677M | 0.035M |
| Total Current Assets | 89.084M | 108.747M | 152.334M | 37.731M | 14.063M |
| Long Term Investments | - | 0M | 0.997M | - | - |
| Short Term Investments | 26.26M | 32.888M | 74.311M | - | - |
| Net Receivables | 0M | 0.012M | 0.246M | 0.5M | 0.21M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | -74.311M | - | - |
| Accounts Payable | 2.112M | 3.155M | 1.394M | 1.481M | 0.295M |
| Accumulated Other Comprehensive Income | -0.001M | -0.03M | -0.049M | - | - |
| Non Currrent Assets Other | 1.034M | 0.744M | 0.102M | 0.014M | - |
| Non Current Assets Total | 13.501M | 13.62M | 14.371M | 0.692M | 0.035M |
| Capital Lease Obligations | 4.463M | 4.842M | 5.365M | 0.621M | 0M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | 42.573M | -75.626M | -0.053M | -0.021M |
| Total Cashflows From Investing Activities | 41.831M | -75.616M | -0.053M | -0.021M |
| Total Cash From Financing Activities | 0.019M | 144.265M | 37.982M | 17.172M |
| Net Income | -50.514M | -33.536M | -17.04M | -7.709M |
| Change In Cash | -2.251M | 37.798M | 23.308M | 12.708M |
| Begin Period Cash Flow | 74.888M | 37.09M | 13.782M | 1.074M |
| End Period Cash Flow | 72.637M | 74.888M | 37.09M | 13.782M |
| Total Cash From Operating Activities | -44.101M | -30.851M | -14.621M | -4.442M |
| Depreciation | 0.797M | 0.159M | 0.079M | 0.018M |
| Other Cashflows From Investing Activities | - | 0.07M | - | - |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | - | - | 0.018M |
| Sale Purchase Of Stock | 0.019M | 144.265M | - | - |
| Other Cashflows From Financing Activities | 0.019M | 23.946M | -0.053M | 17.172M |
| Capital Expenditures | 0.742M | 0.061M | 0.053M | 0.021M |
| Change In Working Capital | 1.717M | 0.9M | 1.253M | 0.437M |
| Other Non Cash Items | -0.166M | 0.13M | -20.664M | 1.476M |
| Free Cash Flow | -44.844M | -30.912M | -14.674M | -4.463M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 736188 |
| 2. | T. Rowe Price Health Sciences | 1 year ago | 604020 |
| 3. | iShares Russell 2000 ETF | 1 year ago | 491452 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 289196 |
| 5. | Fidelity Select Biotechnology | 1 year ago | 232842 |
| 6. | Fidelity Small Cap Index | 1 year ago | 217856 |
| 7. | iShares Russell 2000 Growth ETF | 1 year ago | 145391 |
| 8. | Fidelity Extended Market Index | 1 year ago | 115479 |
| 9. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 113800 |
| 10. | Bridgeway Ultra-Small Company Market | 1 year ago | 109949 |
| 11. | TD Health Sciences - I | 1 year ago | 98938 |
| 12. | Vanguard Russell 2000 ETF | 1 year ago | 84065 |
| 13. | Range Cancer Therapeutics ETF | 1 year ago | 81683 |
| 14. | State St Russell Sm Cap® Indx SL Cl I | 1 year ago | 74700 |
| 15. | NT R2000 Index Fund - NL | 1 year ago | 61053 |
| 16. | NT R2000 Growth Index Fund - NL | 1 year ago | 52972 |
| 17. | Schwab Small Cap Index | 1 year ago | 51835 |
| 18. | NT R2000 Index Fund - DC - NL - 2 | 1 year ago | 48484 |
| 19. | BlackRock Extended Mkt Composite | 1 year ago | 48039 |
| 20. | iShares Micro-Cap ETF | 1 year ago | 47725 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Cormorant Asset Management, LLC | 1 year ago | 3295273 |
| 2. | BlackRock Inc | 1 year ago | 2097406 |
| 3. | Vanguard Group Inc | 1 year ago | 1203666 |
| 4. | Goldman Sachs Group Inc | 1 year ago | 914118 |
| 5. | T. Rowe Price Associates, Inc. | 1 year ago | 910266 |
| 6. | FMR Inc | 1 year ago | 489447 |
| 7. | Geode Capital Management, LLC | 1 year ago | 444233 |
| 8. | State Street Corporation | 1 year ago | 373662 |
| 9. | HighVista Strategies LLC | 1 year ago | 254513 |
| 10. | Northern Trust Corp | 1 year ago | 183927 |
| 11. | TD Asset Management Inc | 1 year ago | 150876 |
| 12. | Bridgeway Capital Management, LLC | 1 year ago | 114049 |
| 13. | Exchange Traded Concepts, LLC | 1 year ago | 98254 |
| 14. | Manufacturers Life Insurance Co | 1 year ago | 91182 |
| 15. | SOUTHPORT MANAGEMENT, L.L.C. | 1 year ago | 90100 |
| 16. | Bank of New York Mellon Corp | 1 year ago | 64029 |
| 17. | Millennium Management LLC | 1 year ago | 63262 |
| 18. | Charles Schwab Investment Management Inc | 1 year ago | 60512 |
| 19. | Morgan Stanley - Brokerage Accounts | 1 year ago | 56148 |
| 20. | Adage Capital Partners Gp LLC | 1 year ago | 50000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...